Blood Glucose Levels in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation

What this Trial Is About

Researchers are investigating how betamethasone treatment affects blood sugar levels in pregnant women without diabetes who are at risk of preterm birth. Betamethasone is typically given to help mature the baby's lungs before an early delivery, but it can cause high blood sugar in mothers, especially those with diabetes. This study focuses on understanding blood sugar changes in non-diabetic pregnant women during this treatment using continuous glucose monitoring. Participants will receive betamethasone as part of their care for threatened preterm birth, either planned or already started within four hours before joining the study. Blood sugar levels will be closely tracked using a continuous glucose monitor over several days during and after the treatment. Blood samples will also be taken for various tests including insulin, inflammatory markers, and ketones. After birth, samples from the umbilical cord will be collected to measure factors related to blood sugar and inflammation. Information about newborn feeding and hypoglycemia will also be recorded. During the study, women will have regular blood tests for up to six days following betamethasone administration. Twice daily urine tests will check for glucose and ketones. The main focus is to observe changes in maternal blood sugar levels before, during, and after treatment. Researchers will also monitor several blood markers and newborn health indicators to better understand the effects of betamethasone. The study aims to improve care by identifying if blood sugar needs closer monitoring during this treatment to protect both mother and baby.

Blood Glucose in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation